Subcutaneous abatacept for the treatment of rheumatoid arthritis
Michael Schiff, Michael Schiff
Abstract
The efficacy, safety and tolerability of i.v. abatacept are well established in patients with active RA. A s.c. abatacept formulation is now available in some countries. Here, we review clinical data for s.c. abatacept. Six trials are presented (Phase II dose-finding study, ACQUIRE, ALLOW, ACCOMPANY, ATTUNE and AMPLE) and issues important to both patients and clinicians are addressed. The primary focus assesses whether the i.v. and s.c. abatacept formulations have similar efficacy, including whether the recommended fixed dose of s.c. abatacept is comparable to the weight-tiered i.v. dosing and whether efficacy is sustained with long-term treatment. Safety and immunogenicity are also discussed, including the short- and long-term safety of s.c. abatacept, and whether immunogenicity is increased following a switch from i.v. to s.c. abatacept, after withdrawal or reintroduction of s.c. abatacept or in the absence of MTX. Year 1 data from the AMPLE study, comparing s.c. abatacept with the TNF antagonist adalimumab, are discussed. Although fewer patient-years of exposure are available for s.c. compared with i.v. abatacept, observations suggest that s.c. abatacept has a similar long-term efficacy to the i.v. formulation, improving the signs, symptoms, disease activity and physical function in patients with RA. With continued treatment, these improvements are maintained over time with high retention rates, similar to i.v. abatacept. s.c. abatacept is associated with low immunogenicity and short- and long-term safety that is consistent with i.v. abatacept. In addition, s.c. abatacept demonstrates comparable efficacy, kinetics of response, safety and radiographic inhibition to adalimumab.
Keywords: abatacept; biologic therapy; rheumatoid arthritis; subcutaneous.
Figures
References
- Yamada A, Salama A, Sayegh M. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13:559–75.
- Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68:1870–7.
- Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
- Kremer JM, Russell AS, Emery P, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70:1826–30.
- Smolen J, Dougados M, Gaillez C, et al. Remission according to different composite disease activity indices in biologic-naïve patients with rheumatoid arthritis treated with abatacept or infliximab plus methotrexate. Arthritis Rheum. 2011;63:1124.
- Westhovens R, Kremer JM, Emery P, et al. Consistent safety and sustained improvement in disease activity and treatment response over 7 years of abatacept treatment in biologic-naïve patients with RA. Ann Rheum Dis. 2009;68:577. (Abstract SAT0108)
- Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23.
- Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68:1708–14.
- Hochberg MC, Westhovens R, Aranda R, et al. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment. Arthritis Rheum. 2010;62:S164.
- Corbo M, Valencia X, Raymond R, et al. Subcutaneous administration of abatacept in patients with rheumatoid arthritis: pharmacokinetics, safety and immunogenicity. Ann Rheum Dis. 2009;68:S574.
- Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum. 2011;63:2854–64.
- Genovese MC, Covarrubias JA, Leon G, et al. The ACQUIRE (Abatacept Comparison of sub[Qu]cutaneous versus intravenous in Inadequate Responders to methotrexatE) trial: a large phase IIIb non-inferiority study. Ann Rheum Dis. 2011;70:OP0023.
- Genovese MC, Cobos AC, Leon G, et al. Subcutaneous (SC) abatacept (ABA) versus intravenous (IV) ABA in patients (pts) with rheumatoid arthritis: long-term data from the ACQUIRE (Abatacept Comparison of sub[QU]cutaneous versus intravenous in Inadequate Responders to methotrexatE) trial. Arthritis Rheum. 2011;63:S150.
- Murthy B, Gao L, Yin J, et al. Pharmacokinetics of subcutaneous abatacept support a fixed dosing regimen in adult patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(Suppl 3):FRI0347.
- Nash P, Nayiager S, Genovese M, et al. Immunogenicity, safety and efficacy of subcutaneous abatacept with or without MTX in patients with rheumatoid arthritis: the Phase III ACCOMPANY study. Arthritis Care Res (Hoboken) 2012 Oct 24. doi: 10.1002/acr.21876. [Epub ahead of print]
- Keystone EC, Kremer JM, Russell A, et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis. 2012;71:857–61.
- Kaine J, Gladstein G, Strusberg I, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study) Ann Rheum Dis. 2012;71:38–44.
- Kaine J, Gladstein G, Strusberg I, et al. Subcutaneous abatacept is effective and well tolerated, with low immunogenicity following temporary withdrawal and re-introduction in the ALLOW LTE. Arthritis Rheum. 2011;63:S853.
- Weinblatt M, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2012;65:28–38.
- Schiff M, Alten R, Weinblatt M, et al. Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. Arthritis Rheum. 2012;64(10 Suppl):S1076.
- Nash P, Ludivico C, Delaet I, et al. Improvements in disease activity and physical function in patients with RA receiving subcutaneous abatacept in the presence or absence of an initial IV loading dose. Ann Rheum Dis. 2011;70:SAT0287.
- Nash P, Ludivico C, Delaet I, et al. Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading dose. Arthritis Rheum. 2011;63:S151.
- Murthy B, Gao L, Vakkalagadda B, et al. Clinical pharmacokinetics of subcutaneous abatacept in the presence or absence of an intravenous loading dose in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(Suppl 3):SAT0284.
- Alten R, Kaine J, Keystone EC, et al. Safety of subcutaneous abatacept in patients with rheumatoid arthritis (RA): integrated analysis of five clinical trials up to 4.5 years. Ann Rheum Dis. 2011;70(Suppl 3):617.
- Alten R, Kaine J, Keystone EC, et al. Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure. Arthritis Rheum. 2011;63:S150.
- Genovese M, Pacheco-Tena C, Covarrubias A, et al. Subcutaneous abatacept: long-term data from the ACQUIRE trial. Arthritis Rheum. 2012;64(10 Suppl):S201.
- Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(Suppl 6):vi3–9.
- Haggerty HG, Abbott MA, Reilly TP, et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol. 2007;34:2365–73.
- Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:S46–56.
- Lunt M, Watson KD, Dixon WG, et al. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2010;62:3145–53.
- Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–6.
- Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69:817–21.
- Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782–9.
- Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:40–6.
- Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010;9:560–4.
- Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739–45.
- Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
- Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011:CD008794.
Source: PubMed